8-K: Rigel Reports Record 2025 Sales, Strong 2026 Outlook

Rigel Pharmaceuticals announced record net product sales and net income for 2025, alongside positive financial guidance for 2026 and progress in its R289 clinical study.

Summary

• Fourth quarter 2025 total revenues were approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million.
• Full year 2025 total revenues were approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million.
• Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit.
• Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing, with completion of enrollment and selection of the recommended Phase 2 dose anticipated in the second half of 2026.
• Preliminary data from the R289 dose expansion phase are expected to be shared by the end of 2026.
• Updated data from the R289 dose escalation phase showed 33% (6/18) of evaluable transfusion-dependent patients achieved red blood cell transfusion independence (RBC-TI 8 weeks) at 500 mg QD and higher doses.
• Pralsetinib demonstrated robust and durable activity against RET fusion-positive solid tumors, including GI tumors, with an overall response rate (ORR) of 67% (26/39) in the efficacy evaluable population from the TAPISTRY study.
• Median overall survival (OS) for pralsetinib in metastatic RET fusion-positive NSCLC was 44.3 months for the overall patient population, with U.S. patients showing a longer median OS of 62.4 months.
• The U.S. FDA approved a Prior Approval supplemental New Drug Application for GAVRETO, updating the U.S. Prescribing Information to add a boxed warning regarding serious infections.
• Rigel met its postmarketing commitment for GAVRETO from its September 2020 accelerated approval.
• A paper detailing final 5-year results for olutasidenib in R/R mIDH1 AML was published, supporting durable responses and a manageable safety profile.
• Cash, cash equivalents and short-term investments as of December 31, 2025, were $155.0 million, compared to $77.3 million as of December 31, 2024.
• For 2026, Rigel anticipates total revenues of approximately $275 to $290 million, including net product sales of $255 to $265 million, and expects to report positive net income for the full year.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, driven by strong financial performance, significant growth in product sales, and promising clinical pipeline advancements, despite a slight dip in 2026 total revenue guidance compared to 2025 actuals due to contract revenue fluctuations.

Positives

• Record net product sales of $65.4 million in Q4 2025, a 41% increase from Q4 2024.
• Record full-year 2025 net product sales of $232.0 million, a 60% increase from 2024.
• Significant net income of $268.1 million in Q4 2025 and $367.0 million for full-year 2025, largely due to a $245.9 million non-cash deferred income tax benefit.
• Strong cash position with $155.0 million in cash, cash equivalents, and short-term investments as of December 31, 2025, nearly doubling from $77.3 million in 2024.
• Positive 2026 outlook with anticipated net product sales of $255-$265 million (an increase from 2025) and positive net income.
• Progress in R289 Phase 1b study for lower-risk MDS, with enrollment in dose expansion ongoing and preliminary data expected by end of 2026.
• R289 showed 33% red blood cell transfusion independence (RBC-TI 8 weeks) in evaluable transfusion-dependent patients at 500 mg QD and higher doses in the dose escalation phase.
• FDA approval of a Prior Approval supplemental New Drug Application for GAVRETO, and meeting its postmarketing commitment for GAVRETO.
• Publication of 5-year data for olutasidenib in R/R mIDH1 AML, supporting durable responses and manageable safety.
• Pralsetinib demonstrated robust and durable activity against RET fusion-positive solid tumors, including GI tumors, with an overall response rate (ORR) of 67% (26/39) from the TAPISTRY study.
• Longer median overall survival (OS) of 62.4 months for pralsetinib in U.S. patients with metastatic RET fusion-positive NSCLC, compared to 44.3 months for the overall patient population in the ARROW study.

Negatives

• GAVRETO's U.S. Prescribing Information was updated to add a boxed warning regarding serious infections, including opportunistic infections.
• Total costs and expenses increased in Q4 2025 to $46.6 million from $40.9 million in Q4 2024, and for the full year 2025 to $168.8 million from $155.1 million in 2024, mainly due to increased R&D costs and higher personnel-related costs.
• Contract revenues decreased in Q4 2025 to $4.4 million from $11.1 million in Q4 2024.
• The 2026 anticipated total revenues of $275-$290 million are slightly lower than the 2025 actual total revenues of $294.3 million, primarily due to expected lower contract revenues.

Risks

• Risks and uncertainties associated with the commercialization and marketing of TAVALISSE, GAVRETO, and REZLIDHIA.
• Risks that the FDA, European Medicines Agency, PMDA, or other regulatory authorities may make adverse decisions regarding TAVALISSE, GAVRETO, REZLIDHIA, or R289.
• Operational, regulatory, or other risks that can affect the timing of enrollment and data availability for R289 clinical development.
• Risks that clinical trials may not be predictive of real-world results or of results in subsequent clinical trials.
• Risks that TAVALISSE, GAVRETO, REZLIDHIA, or R289 may have unintended side effects, adverse reactions, or incidents of misuses.
• The availability of resources to develop or market Rigel's product candidates.
• Market competition.
• Unanticipated business needs and other developments, including potential partnering, licensing, or other collaboration arrangements, which could impact Rigel's funding needs or other internal resource demands.

Future Outlook

Rigel anticipates full-year 2026 total revenues of approximately $275 to $290 million, including net product sales of $255 to $265 million and contract revenues of $20 to $25 million. The company also expects to report positive net income for the full year 2026 while continuing to fund existing and new clinical development programs.

Management Comments

• "I am proud to highlight Rigel's tremendous progress during 2025 across each of the key value drivers of our business. We delivered record net product sales, total revenues and net income while making meaningful advances in our Phase 1b study of R289 in lower-risk MDS." Raul Rodriguez, Rigel's president and CEO.
• "These 2025 accomplishments set the stage for a strong 2026, as reflected in our financial guidance and our plans to advance our R289 program in lower-risk MDS and other potential indications." Raul Rodriguez, Rigel's president and CEO.

Industry Context

StockSavvy.ai notes that Rigel's focus on hematologic disorders and cancer, particularly with targeted therapies like GAVRETO and REZLIDHIA, aligns with the broader biotechnology industry trend towards precision medicine. The strong growth in product sales for TAVALISSE, GAVRETO, and REZLIDHIA indicates successful commercialization in competitive therapeutic areas, while the advancement of R289 in MDS addresses a significant unmet medical need in a rare blood disorder. The positive net income, despite increased R&D, suggests effective cost management relative to revenue growth, a key indicator for biotech sustainability.

Comparison to Industry Standards

• The 67% Overall Response Rate (ORR) for pralsetinib in RET fusion-positive solid tumors (including GI cancers) from the TAPISTRY study is a strong indicator of efficacy, comparable to or exceeding ORRs seen with other targeted therapies in similar advanced solid tumor settings, such as other RET inhibitors like selpercatinib which have shown ORRs in the range of 60-70% in RET fusion-positive NSCLC.
• The median Overall Survival (OS) of 62.4 months for pralsetinib in U.S. patients with metastatic RET fusion-positive NSCLC is notably high, suggesting a significant survival benefit. This compares favorably to historical data for chemotherapy in advanced NSCLC (typically 8-12 months) and even to some other targeted therapies, positioning pralsetinib as a highly effective treatment in this specific patient population.
• The 33% red blood cell transfusion independence (RBC-TI 8 weeks) achieved by R289 in lower-risk MDS patients is a clinically meaningful outcome, as transfusion dependence is a major burden for these patients. This result is competitive with other emerging therapies for lower-risk MDS, such as luspatercept, which has shown RBC-TI rates in the range of 30-40% in specific MDS patient subgroups.

Management Changes

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased net income, and positive 2026 outlook, potentially leading to increased share value.
• Patients: Positive impact from continued clinical development of R289 for lower-risk MDS, and further data supporting the benefits of olutasidenib and pralsetinib for various cancers, offering new or improved treatment options.
• Employees: Potential positive impact from company growth and continued investment in R&D, suggesting job stability and potential for expansion.
• Regulatory Authorities: Continued engagement with FDA for approvals and post-marketing commitments, demonstrating compliance and ongoing product lifecycle management.

Next Steps

• Complete enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS in the second half of 2026.
• Select the recommended Phase 2 dose for R289 for future clinical studies in the second half of 2026.
• Share preliminary data from the dose expansion phase of the R289 study by the end of 2026.
• Continue funding existing and new clinical development programs in 2026.
• Hold a conference call and webcast on March 3, 2026, at 4:30 p.m. Eastern Time.

Key Dates

Recommendation

The company reported record net product sales and net income for 2025, significantly exceeding previous year's performance. The 2026 outlook projects continued growth in net product sales, a key operational metric, and positive net income. Clinical pipeline advancements, particularly with R289 showing promising early data and pralsetinib demonstrating robust efficacy and impressive overall survival in specific cancer types, indicate strong future growth potential. The substantial increase in cash reserves further strengthens the company's financial position. Despite a minor decrease in projected total revenue for 2026 compared to 2025 actuals due to contract revenue fluctuations, the core business performance and pipeline progress make this a compelling investment.

Keywords

Rigel Pharmaceuticals, RIGL, biotechnology, hematologic disorders, cancer, TAVALISSE, fostamatinib, GAVRETO, pralsetinib, REZLIDHIA, olutasidenib, R289, MDS, AML, NSCLC, ITP, financial results, Q4 2025, full year 2025, 2026 outlook, clinical trials, FDA approval, oncology, rare diseases